Novo inks $1.4B pact with Orbis to push oral macrocycle therapies
Novo, which recently rebranded from Novo Nordisk, struck a potential $1.4 billion biobucks deal with Orbis Medicines to develop orally bioavailable macrocycle therapies for cardiometabolic diseases, leveraging Orbis's AI-enabled nGen platform. The agreement includes upfront and milestone payments plus a strategic investment and marks Orbis’s first Big Pharma pact, with exact targets not disclosed.